Cardiovascular Systems touts 1-year, sub-analysis data from Liberty PVI study

Cardiovascular Systems (NSDQ:CSII) today released both 1-year and a sub-analysis results from the Liberty 360 clinical trial of peripheral interventions, including those using its DiamondBack 360 coronary orbital atherectomy system. The 1,200 patient study aimed to evaluate acute and long-term clinical outcomes of peripheral interventions for patients with peripheral artery disease, with the most common device used being the company’s Diamondback 360, the St. Paul, Minn.-based company said. 1-year outcomes were presented at the 2017 Amputation Prevention Symposium in Chicago by Dr. Jihad Mustapha of Michigan’s Metro Health Hospital. “Our commitment to clinical rigor is key to our success and growth plans. The Liberty 360 study continues to reinforce the importance of endovascular intervention for this difficult-to-treat patient population, with a particular focus on amputation prevention for patients with PAD, and specifically critical limb ischemia,” prez & CEO Scott Ward said in a press release. Results from the trial indicated that at 12 months, individuals with critical limb ischemia spanning Rutherford Classifications between 4 and 5 had a 96% freedom from amputation, while those with an RC6 rating had an 81.7% freedom from amputation. Data also indicated that CLI patients had improvements in RC, wound healing and quality of life. “Liberty 360 represents as close to a real-world experience as possible with various endovascular strategi...
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Vascular Cardiovascular Systems Inc. Source Type: news